Clinical Trial Evaluating the Safety and Efficacy of Levamisole in Loa Loa Microfilaremic Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

255 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-01-16

Study Completion Date

2021-07-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims at evaluating the safety and efficacy of levamisole in patients with loiasis infection.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

21-day Double-blind Trial of Albendazole in Adults With Loa Loa Microfilaremia

NCT06613997

Loiasis With Positive Blood Microfilaremia Loiasis

NOT_YET_RECRUITING PHASE3

Clinical Trial Evaluating the Safety and Efficacy of Moxidectin 2 mg Ivermectin-controlled in Loa Loa Microfilaremic Patients

NCT04049851

Onchocerciasis, Ocular Loiasis

COMPLETED PHASE2

Loiasis Cross-reactive Antigenemia and Treatment-related Adverse Events

NCT05085665

Loiasis

COMPLETED PHASE4

Emodepside Phase II Trial for Treatment of Onchocerciasis

NCT05180461

Onchocerciasis

ACTIVE_NOT_RECRUITING PHASE2

Pharmacokinetics/Safety of Miltefosine Allometric Dose for the Treatment of Visceral Leishmaniasis in Children in Eastern Africa

NCT02431143

Visceral Leishmaniasis

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This clinical trial will be conducted in Republic of Congo. This is a pragmatic and adaptative randomized, double-blind clinical trial. Levamisole will be tested at 1 and 1,5 mg/kg, and compared to placebo (36:36:36); or 2,5 mg/kg compared to placebo (36:36) in case of adaptation of the dose for cohorts II and III.

We will perform three cohorts of patients according to the microfilarial density : 1-1,999 mf/ml, 1-14,999 mf/ml, and all microfilaremic individuals; in order to respect the safety potentially related to loiasis.

The first cohort was to evaluate the most appropriate dose of levamisole, with a possibility to increase (to 2.5 mg/kg) the dose of levamisole for the cohorts II and III in case of lack of efficacy and in case of good safety profil.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Onchocerciasis, Ocular Loiasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LEV 1 mg/kg

A combinaison of LEV 10 mg, 50 mg, and placebo will be adapted to the weight ; all the tablets will be blinded, and each participant will receive 5 tablets.

Intervention Type DRUG

LEV 1,5 mg/kg

A combinaison of LEV 10 mg, 50 mg, and placebo will be adapted to the weight ; all the tablets will be blinded, and each participant will receive 5 tablets.

Intervention Type DRUG

LEV 2,5 mg/kg

A combinaison of LEV 10 mg, 50 mg, and placebo will be adapted to the weight ; all the tablets will be blinded, and each participant will receive 5 tablets.

Intervention Type DRUG

Placebo

5 tablets of placebo will be administrated to the participants.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Written consent written, signed (or with thumbprint) and dated
* Aged 18 to 65 inclusive
* Individual microfilarial density ≥ 1mf/mL
* Body weight ≥ 40 kg in women and ≥ 45 kg in men; and less than 85 kg
* In good health condition, as determined by the medical questionnaire and the general clinical examination: absence of acute or chronic infection

Exclusion Criteria

* Participation in any study other than purely observational, in the 4 weeks preceding this study (determined by the theoretical date of administration of LEV or placebo).
* Any vaccination in the 4 weeks preceding this study.
* Acute infection requiring a treatment in the 10 days preceding this study, determined by the anamnesis during the medical interview (example: pulmonary infection, ENT, digestive, cutaneous, with implementation of an antibiotic treatment or not)
* Warfarin treatment
* Treatment with clozapine, phenythiazines, sulfasalazine, carbamazepine, synthetic antithyroid, ticlopidine, cimetidine, and gold salts: whether it is a long-term treatment, or a treatment given in a single dose 10 days before the start of treatment for the clinical trial (precaution of use compared to the risk of agranulocytosis of immuno-allergic or toxic origin)
* Known immunosuppressive pathology
* Past or current history of neurological (including epilepsy) or neuropsychiatric disease
* History of agranulocytosis
* Consumption of alcohol, taking cocaine or other drugs of abuse in the 72 hours preceding the administration of the treatment of the test determined by the anamnesis during the medical interview
* Any condition, in the opinion of the investigator, which exposes the subject to an undue risk
* Known intolerance to levamisole
* Subjects who gave blood in the 8 weeks before entry into the study, with a standard volume (\> 500 mL)
* During the clinical examination: symptoms, physical signs or biological constants suggestive of systemic disorders, including renal, hepatic, cardiovascular, pulmonary, cutaneous, immunodeficiency, psychiatric disorders and other abnormalities likely to interfere with the interpretation results of the test. The doctor may then give a favorable or unfavorable opinion for the inclusion of the participant
* Taking IVM and / or LEV during the last six months; and / or mebendazole or albendazole in the last month
* Pregnant and lactating women (based on self-declaration)

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes